Chronic Subdural Hematoma Clinical Trial
— DISHOfficial title:
Association Between Dietary Factors and Chronic Subdural Hematoma: a Multicenter Case-control Study
NCT number | NCT05599217 |
Other study ID # | HX-B-2022062 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | March 13, 2023 |
Est. completion date | March 31, 2025 |
A prospective, multicenter, case control trial is designed to compare difference in dietary and nutritional factors in patients with and without chronic subdural hematoma.
Status | Recruiting |
Enrollment | 420 |
Est. completion date | March 31, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Case group (CSDH group) Inclusion Criteria: - Patients (18 years to 90 years) presenting with clinical symptoms and neurological deficits of CSDH. - CSDH verified on cranial computed tomography or magnetic resonance imaging. - Written informed consent from patients or their next of kin according to the patient's cognitive status. Control group (Healthy group) Inclusion Criteria: - non-CSDH patients (18 years to 90 years) with matched age and gender. - Written informed consent from patients or their next of kin according to the patient's cognitive status. Exclusion Criteria for both case and control group: - Previous intracranial surgery for any neurological disorders but chronic subdural hematoma before. - CSDH turned from acute subdural hematoma. - Existing malignant tumors, poor medication condition or severe comorbidity. - Difficulty in feeding requiring long-term enteral or parenteral nutrition support. - Dietary and nutritional survey is estimated to be completed difficultly. - Reproductive-age women without verified negative pregnancy testing. - Participating in other research. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Tiantan Hospital, Capital Medical University | Beijing | |
China | Huangshan City People's Hospital | Huangshan | Anhui |
China | First People's Hospital of Lianyungang | Lianyungang | Jiangsu |
China | People's Hospital of Ningxia Hui Autonomous Region | Yinchuan | Ningxia |
Lead Sponsor | Collaborator |
---|---|
Beijing Tiantan Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference in dietary intakes | Difference in dietary intakes assessed by Food Frequency Questionnaire, a common method for measuring dietary intake in large epidemiological studies. | When subjects are enrolled | |
Primary | Difference in Dietary Inflammatory Index score | The Dietary Inflammatory Index (DII) score of the current nutritional status of patients with and without CSDH will be evaluated. The amounts of nutrients will be calculated using last 3-month nutrient analysis program. DII score will calculate from these foods. The z-score must first be calculated. To calculate the z-score, the standard global consumption amount is subtracted from the average consumption amount of the individual. The result obtained is divided by the standard deviation value. The z score found with this result is converted to the percentile score. The percentile value is multiplied by the full inflammatory effect score. DII is obtained as a result of summing the scores calculated for all nutrients. Found DII is an indicator of the inflammatory load of the individual's daily diet. | When subjects are enrolled | |
Primary | Difference in nutritional status | Difference in nutritional status measured by Mini-Nutritional Assessment. | When subjects are enrolled | |
Primary | Difference in frailty status | Difference in frailty status measured by Modified Frailty Index. Modified Frailty Index ranges from score 0 to 1, and frail status is defined as a score of =0.27. | When subjects are enrolled | |
Secondary | Difference in gut microbiota measured by 16S rRNA between case group and control group | Fecal sample will be measured by 16S rRNA sequencing. The alpha and beta diversity of gut microbiota between the groups will be analyzed, including a series of statistical analysis indexes such as Chao, Shannon, Simpsonace, Simpson and Coverage, in order to reflect the microbial community diversity. Based on the results of species annotation, the community histogram, the community heatmap and the Wayne map will be used to analyze the species composition of the sample, in order to explore the relationship between the species and the sample, and analyze the key microflora in the sample. The PCA, PCoA and NMDS analysis will be used to assess the similarities and differences in species composition between groups. To further screen the species with significant differences, the LEfSe difference discriminant analysis will be used. | When subjects are enrolled | |
Secondary | Difference in metabolomics of gut, urine, and serum between case group and control group | Changes of metabolites in gut, urine, and serum will be measured by metabolomic mass spectrometry. | When subjects are enrolled |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06347796 -
Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study
|
N/A | |
Recruiting |
NCT04065113 -
Middle Meningeal Artery Embolization for Chronic Subdural Hematoma
|
N/A | |
Recruiting |
NCT02938468 -
Mgt of Chronic Subdural Hematoma Using Dexamethasone
|
Phase 2/Phase 3 | |
Completed |
NCT03307395 -
Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma
|
N/A | |
Terminated |
NCT04502745 -
A Study to Evaluate Endoscope-assisted, Minimally-invasive Cortical Access System for Chronic Subdural Evacuation
|
N/A | |
Terminated |
NCT03353259 -
Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery
|
Phase 2/Phase 3 | |
Recruiting |
NCT02568124 -
Tranexamic Acid in Chronic Subdural Hematomas
|
Phase 2/Phase 3 | |
Completed |
NCT02282228 -
Detecting Chronic Subdural Hematoma With Microwave Technology
|
N/A | |
Recruiting |
NCT05143216 -
High Concentration Oxygen Therapy for Pneumocephalus in Chronic Subdural Haematoma: A Prospective Observational Study
|
||
Active, not recruiting |
NCT04816591 -
Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA
|
N/A | |
Recruiting |
NCT06401772 -
The Effectiveness and Safety of Body Posture in Preventing Postoperative Recurrence for Chronic Subdural Hematoma
|
N/A | |
Completed |
NCT06134206 -
Burr Hole Ultrasound Study
|
N/A | |
Recruiting |
NCT03666949 -
General Anesthesia Versus Locoregional Anesthesia for Evacuation of Chronic Subdural Hematoma
|
N/A | |
Recruiting |
NCT03280212 -
Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma
|
Phase 3 | |
Completed |
NCT03447327 -
Outcome of Single Burr Hole Under Local Anaesthesia in the Management of Chronic Subdural Hematoma
|
N/A | |
Recruiting |
NCT05374681 -
Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization
|
N/A | |
Recruiting |
NCT05267184 -
Swedish Trial on Embolization of Middle Meningeal Artery Versus Surgical Evacuation in Chronic Subdural Hematoma
|
N/A | |
Not yet recruiting |
NCT05900557 -
Neurologic Deficits and Recovery in Chronic Subdural Hematoma
|
N/A | |
Completed |
NCT02757235 -
The Swedish Study of Irrigation Fluid Temperature in the Evacuation of Chronic Subdural Hematoma
|
N/A | |
Terminated |
NCT02111785 -
Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma
|
Phase 2/Phase 3 |